Inhibitex’s hepatitis C drug, INX-189, is being studied in the second of three phases of human trials generally needed for FDA approval. The treatment is part of a drug class known as nucleotide polymerase inhibitors. Public since 2004, the company also is studying a treatment for shingles, but Russo calls INX-189 “the real value driver.” He also says he believes Inhibitex will seek a partner to help develop the hepatitis drug.
http://www.minyanville.com/businessmarkets/articles/hepatitis-c-pharmasset-vertex-merck-johnson/8/25/2011/id/36565?camp=syndication&medium=portals&from=yahoo
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM
All Things Mobile Analytic, Inc. Reports Major Growth with Over $11 Million in Revenue • ATMH • Aug 22, 2024 7:19 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM